Cytotoxic T cell depletion with increasing epithelial abnormality in women with benign breast disease

Sabina Adhikary1,2 · Tanya L. Hoskin3 · Melody L. Stallings-Mann4 · Muhammad Arshad5 · Marlene H. Frost6 · Stacey J. Winham3 · Alvaro Peña5 · Delphine J. Lee7 · Linda M. Murphy5 · Michele Rakoff8 · Lori A. Denison9 · Keith L. Knutson10 · Derek C. Radisky4 · Daniel W. Visscher11 · Amy C. Degnim5

Received: 23 August 2019 / Accepted: 8 November 2019 / Published online: 13 January 2020
© The Author(s) 2020

Abstract
Purpose We quantified cytotoxic T cells in nonmalignant breast tissues from women with and without subsequent breast cancer to assess evidence of whether immunosurveillance may be suppressed prior to tumor development.
Methods We used an age-matched set of breast tissues from women with benign breast disease (BBD) who subsequently developed breast cancer (BBD with later BC), women with BBD who remained cancer free (BBD cancer-free), and normal Komen Tissue Bank (KTB) tissue donors (KTB controls). We evaluated terminal duct lobular units (lobules) for degree of epithelial abnormality and density of dual-positive CD8/CD103 T cells, as CD103+ cells are thought to be a subset of CD8+ cytotoxic T cells located primarily in the intraepithelial compartment.
Results In 10 sets of age-matched women, 256 breast lobules were studied: 85 in BBD women with later BC, 85 in BBD cancer-free women, and 86 in KTB donors. The majority of all lobules were histologically normal (N= 143, 56%), with 65 (25%) nonproliferative fibrocystic change, and 48 (19%) proliferative epithelial change (with or without atypia). In BBD women with later BC, median CD8+/CD103+ cell density was 39.6, 31.7, and 10.5 cells/mm² (p=0.002) for normal, non-proliferative, and proliferative lobules. In BBD cancer-free women, median CD8+/CD103+ cell density values were 46.7, 14.3, and 0 cells/mm² (p=0.004) respectively. In KTB donors, CD8+/CD103+ cell density was not significantly different across the lobule types (medians 0, 5.8, 10.7, p=0.43).
Conclusion In women with BBD, breast lobules with increasing epithelial abnormality show significant decreases in cytotoxic T cells as measured by CD8/CD103 staining, suggesting that impaired immunosurveillance may be a component of the earliest stages of breast cancer development.

Keywords Breast cancer · Cytotoxic T cells · Immunosurveillance · Cancer risk · Benign breast disease · Intraepithelial lymphocytes

Abbreviations
BBD Benign breast disease
KTB Komen Tissue Bank
IEL Intraepithelial lymphocyte

Background
The immunosurveillance hypothesis was introduced a century ago by Ehrlich [1] and has gained support with increasing evidence from both animal models and human data that cytotoxic T cells may have a critical role. CD103 expressing CD8 T cells are lymphocytes intimately associated with mucosal surfaces such as intestinal epithelium [2]. They have been called “intraepithelial lymphocytes” (IELs) and have been characterized as a resident memory type of CD8 T cells with potent cytolytic capacities and a role in immune surveillance [3]. Other recent studies show improved outcomes in epithelial tumors with CD103 expressing CD8 T cells such as lung [4], ovarian [5], endometrial [6], and breast cancer [7]. In most of these studies, the CD103-expressing T cells were predominantly intraepithelial and CD103+ cells were more strongly associated with outcomes than CD8+ T cells. We recently reported on immune cells in normal and premalignant breast tissues, with a finding of CD8+ T cells in close association with breast epithelium,
representing the main characteristic of mucosal IELs [8]. Therefore, we hypothesized that breast epithelium also harbors similar cytotoxic T cells that may play a role in antitumor immunity. Our specific objective for this project was to quantify dual-positive CD8/CD103 cells in lobules from a case-control set of breast tissues with benign premalignant findings and to investigate associations with breast epithelial abnormalities, as progressive epithelial proliferation in BBD is associated with increasing breast cancer risk [9]. Dual-positive CD8/CD103 stained cells constituted the T cell population of interest as distinct from other CD103 positive cells such as dendritic cells [10].

Methods

Study design and breast tissue samples

We obtained Institutional Review Board approval prior to conducting this research. We utilized samples from an existing study of breast tissues from normal donor women and women with benign breast disease [8]. Briefly, normal breast tissues were obtained from the Susan G. Komen® for the Cure Tissue Bank at IU Simon Cancer Center (i.e. Komen Tissue Bank = KTB), a unique resource of tissue from donor women with no known clinical breast abnormalities [11]. Breast tissues with benign disease were obtained from the Mayo benign breast disease (BBD) Cohort [9], a well-annotated cohort of 13,000 women with follow-up information on later breast cancer events. Within the cohort, a nested set of 100 cases (BBD women with later BC) and 100 controls (BBD cancer-free women) were randomly selected from the latter years of the cohort (1992–2001) and were matched on age, year at biopsy, and length of follow-up. Then an age-matched normal breast tissue donor was randomly selected from the KTB samples to create an age-matched triplet: KTB (or all lobules if < 10 present) were selected, circled digitally, and annotated using Imagescope. Each circled lobe was individually classified as normal, nonproliferative, or proliferative (with or without atypia), according to established criteria that are based upon the degree of epithelial proliferation and cytologic and architectural atypia, as these categories have stratified later BC risk in multiple studies [9, 12]. Examples of nonproliferative lesions include columnar cell alteration, cystic change, fibroadenoma, apocrine metaplasia; proliferative lesions include columnar cell hyperplasia, usual or florid ductal hyperplasia, radial scar, sclerosing adenosis, flat epithelial atypia, and atypical hyperplasia. A serial formalin-fixed paraffin-embedded tissue section was stained for CD8 and CD103 and also digitally scanned scanned with the Aperio Scanscope® FL slide scanner (Leica Biosystems®) using the 20 × objective lens. Matched samples (KTB donor, BBD woman with later BC, BBD cancer-free woman) underwent immunostaining within the same batch to minimize batch effects. The following immunostains were performed with the following antibodies: CD8 (DAKO clone C4/188B, 1:100) and secondary antibody conjugated with AlexaFluor 488 (Life technology, 1:1000); CD103 (AbCam clone EPR4166, 1:2500) and secondary antibody conjugated with AlexaFluor 547 (Life technology, 1:1000).

Samples were deparaffinized with 3 changes of xylene and rehydrated in a series of ethanol baths (100%, 90%, and then 70% Ethanol) and rinsed well in running distilled water. Slides were then placed in a preheated Antigen Retrieval Solution (pH 8.0 EDTA buffer, Vector Lab) for 25 min and then cooled in the buffer for 30 min followed by a 5 min rinse in running distilled water. After the heat-inactivated epitope retrieval step, slides were placed on the DAKO Autostainer for the following procedure (at room temperature). Sections were incubated with phosphate buffered saline (PBS) containing 1% bovine serum albumin (BSA), 2% fetal bovine serum (FBS) to block non-specific staining for 30 min. Sections were incubated in primary antibody at dilutions listed above for 60 min at room temperature. Sections were rinsed with PBS three times, followed by another 60-min incubation with secondary antibody as listed above. The slides were rinsed with PBS three times. Sections were then mounted with 1 drop of Prolong Diamond Antifade Mountant and coverslipped. Digital images were analyzed using Aperio ImageScope Software, version 12.1.0.5029 (Leica Biosystems®, Buffalo Grove, IL). The annotated lobules from the H&E slide were identified; then each lobe was circled digitally and the area was calculated. The RGB image was unmixed into separate channels for absorbance at 488 and 594. Within each lobe, positive cells were annotated individually for each color (with all other colors masked). After all positive cells were identified, colors and
annotations were unmasked, and both singly and double positive cells were counted.

**Statistical analysis**

Cell densities were calculated as the number of positively stained cells per mm² within each outlined lobule area. Number of CD8+/CD103+ cells was analyzed as a count variable using a negative binomial regression model with the logarithm of the lobule area as offset. A generalized linear mixed model approach was used to account for the correlation among multiple lobules measured for each subject. Analysis was performed using PROC GLIMMIX in SAS® (SAS® Institute Inc., Version 9.4). p values < 0.05 were considered statistically significant.

**Results**

**Characteristics of subjects**

The median age was 50 years (range: 40–63 years) and was the same in all three groups because subjects were individually age-matched. Among the 10 BBD cancer-free subjects, median cancer-free follow-up time was 21 years (range 12–27 years). Among the 10 BBD women with later breast cancer, the median time between benign biopsy and cancer development was 8 years (range 2–14 years). The subsequent breast cancer was ER+/PR+ DCIS in one patient and invasive breast cancer in the remaining nine; the invasive breast cancers were 6 HR+/HER2−, 1 HR+/HER2+, 1 HR−/HER2−, and 1 HR−/HER2 unknown. Four subjects had atypical hyperplasia (a known high risk lesion), two who developed breast cancer and two who remained cancer-free.

**Characteristics of tissue samples and lobules**

Among the 30 samples from the 10 age-matched triplets, 256 lobules were evaluated: 86 in normal KTB donors, 85 in BBD women with later BC, and 85 in BBD cancer-free women. The majority of all lobules were histologically normal (N = 143, 56%), with 65 (25%) nonproliferative fibrocystic change, and 48 (19%) proliferative epithelial change (with or without atypia), see Table 1. The three groups differed significantly on lobule type distribution (p < 0.001), with normal lobules constituting 76% of the lobules in normal KTB donors versus 49% in BBD cancer-free women and 42% in BBD women with later BC. Proliferative lobules were present in 4 normal KTB donors, 4 BBD cancer-free women, and 8 BBD women with later BC.

**Distribution and frequency of CD8+/CD103+ T cells**

T cells stained dual-positive for CD8/CD103 were uniformly located in direct association with epithelial cells (Fig. 1). Density of CD8+/CD103+ cells was right skewed, with 72% of lobules having < 50 cells/mm² and 97% with < 200 cells/mm². CD8+/CD103+ cell density varied both across samples and within the lobules of individual samples (Fig. 2).

**CD8+/CD103+ T cell density and association with epithelial abnormality**

CD8+/CD103+ cell density was not significantly different across the three sample groups (p = 0.98) nor across lobule types in breast tissues from the normal donors (p = 0.43, Table 2). However, in benign breast disease tissues, CD8+/CD103+ cell density decreased significantly in lobules with increasing epithelial abnormality, in both BBD women with later BC and BBD cancer-free women (Table 2; Fig. 3). Among BBD women with later BC, median CD8+/CD103+ cell density was 39.6, 31.7, and 10.5 cells/mm² (p = 0.002) for normal, nonproliferative, and proliferative lobules. Among BBD cancer-free women, median CD8+/CD103+ cell density values were 46.7, 14.3, and 0 cells/mm² respectively (p = 0.004). Only 4 subjects in the study sample had atypical hyperplasia (AH), thus severely limiting our ability to analyze this subgroup separately. Descriptively, however, the same trend observed in the BBD subjects overall (i.e. decreasing CD8/CD103(+) T cell density with increasing lobule abnormality) was present in the patients with AH, with median CD8/CD103(+) T cell density 48.1 cells/mm² in normal lobules, 14.5 cells/mm² in fibrocystic nonproliferative lobules, and 7.9 cells/mm² in proliferative lobules.

**Table 1** Distribution of lobule types in each sample group

| Lobule type                        | BBD women with later BC N = 85 lobules | BBD cancer-free women N = 85 lobules | KTB normal donors N = 86 lobules | Total N = 256 lobules |
|-----------------------------------|----------------------------------------|---------------------------------------|----------------------------------|----------------------|
| Normal                            | 36 (42.4%)                             | 42 (49.4%)                            | 65 (75.6%)                       | 143 (55.9%)          |
| Fibrocystic nonproliferative      | 21 (24.7%)                             | 32 (37.6%)                            | 12 (14.0%)                       | 65 (25.4%)           |
| Fibrocystic proliferative/atrophia| 28 (32.9%)                             | 11 (12.9%)                            | 9 (10.5%)                        | 48 (18.8%)           |
Discussion

In this study, we found that CD8+/CD103+ lymphocytes...
are closely associated with the epithelium in breast lobules, and importantly that the density of these cells was significantly lower in lobules with increasing degrees of epithelial abnormality within BBD cases and controls. Although these findings are limited to a small sample size, they are consistent with a protective immunologic function of intraepithelial cytolytic T cells similar to that described in the gut, and they support the possibility of a mucosal immune system in normal human breast that may have a role in tumor immunosurveillance.

CD103 expressing CD8 T cells were first identified as lymphocytes associated with human intestinal epithelium [2] and have been investigated most extensively in that organ. These cells adhere to the epithelial cells via the interaction of CD103 with epithelial E-cadherin [13] and can directly lyse epithelial tumor cells by releasing lytic granules such as granzyme B upon epithelial E-cadherin and CD103 interaction [14, 15], thus helping to maintain epithelial integrity. Lymphoepithelial interactions have been reported to play a major role in mucosal homeostasis in the gut. Secreted growth factors and cytokines as well as the physical interactions between the two cell types help keep the homeostasis. This balance can easily be disrupted during chronic inflammation. In benign breast disease tissues, we observe decreasing CD8+/CD103+ cells with increasing epithelial proliferation. This is particularly interesting given that our previous study showed higher densities of other immune cell types in lobules of BBD compared to normal tissues, suggesting greater inflammation in these tissues [8]. Activation of NFκb, a hallmark of inflammation, is a major factor in downregulation of E-cadherin in epithelial cells [16]. Our observations that CD8+/CD103+ cell density (1) decreased with increasing epithelial proliferation in BBD lobules, and (2) did not differ significantly across lobule types in breast tissues from normal donors are compatible with other published results on IELs and chronic inflammation in the gut mucosa and thus consistent with a possible mechanism of insufficient homing and impaired surveillance.

**Table 2** Median (range) of CD8+/CD103+ cell density (#/mm²) by lobule type and sample group

| Group                   | Median (range) | N lobules |
|-------------------------|----------------|-----------|
| BBD women with later BC |                |           |
| All lobules             | 22.0 (0–314.2) | N=85      |
| Normal                  | 39.6 (0–156.9) | N=36      |
| Fibrocystic nonproliferative | 31.7 (0–314.2) | N=21      |
| Fibrocystic proliferative | 10.5 (0–244.7) | N=28      |
| BBD cancer-free women   |                |           |
| All lobules             | 20.2 (0–183.8) | N=85      |
| Normal                  | 46.7 (0–183.8) | N=42      |
| Fibrocystic nonproliferative | 14.3 (0–143.7)| N=32      |
| Fibrocystic proliferative | 0 (0–80.6)    | N=11      |
| KTB normal donors       |                |           |
| All lobules             | 4.2 (0–976.4)  | N=86      |
| Normal                  | 0 (0–976.4)    | N=65      |
| Fibrocystic nonproliferative | 5.8 (0–467.4) | N=12      |
| Fibrocystic proliferative | 10.7 (0–261.9)| N=9       |

**Conclusion**

In conclusion, in women with BBD, breast lobules with increasing epithelial abnormality show significant decreases in cytotoxic T cells as measured by CD8+/CD103+ staining. These early findings in a small sample size add support to further study the theory that a dysfunctional immune state and impaired tumor immunosurveillance contribute to evolution of breast cancer.

**Acknowledgements** We thank contributors, including Indiana University, who collected samples used in this study, as well as donors and their families, whose help and participation made this work possible. Sincere thanks to Marilyn Churchward for assistance with manuscript preparation.

**Authors’ contributions** Authors SA, MR, THL, DCR and ACD conceived and designed the study. SA, MSM, MA, AP, LMM, DJL, and KTB normal donors. There are no business relationships from any of the authors that may lead to a conflict of interest. None of the funding bodies participated in the direct conduct of the study or in manuscript writing.

**Data availability** The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request, conditional upon approval of the request by the Mayo Clinic Institutional Review Board.

**Compliance with ethical standards**

**Conflicts of interest** The authors declare that they have no conflict of interest.

**Informed consent** Samples utilized from an existing study of breast tissues from normal donor women and women with benign breast dis-
Fig. 3 CD8+/CD103+ density by epithelial proliferation. a BBD women with later BC (N=65 lobules, p=0.01). b BBD cancer-free women (N=85 lobules, p<0.001). c KTB normal tissue donors (N=86 lobules, p=0.51). Boxplots demonstrate interquartile range and median values.
10. Johansson-Lindbom B, Svensson M, Pabst O, Palmqvist C, Marquez G, Forster R, Agace WW (2005) Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing. J Exp Med 202(8):1063–1073. https://doi.org/10.1084/jem.20051100

11. Degnim AC, Visscher DW, Hoskin TL, Frost MH, Vierkant RA, Vachon CM, Shane Pankratz V, Radisky DC, Hartmann LC (2012) Histologic findings in normal breast tissues: comparison to reduction mammaplasty and benign breast disease tissues. Breast Cancer Res Treat 133(1):169–177. https://doi.org/10.1007/s10549-011-1746-1

12. Dupont WD, Page DL (1985) Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312(3):146–151. https://doi.org/10.1056/NEJM198501173120303

13. Schon MP, Arya A, Murphy EA, Adams CM, Strauch UG, Agace WW, Marsal J, Donohue JP, Her H, Beier DR, Olson S, Lefrancois L, Brenner MB, Grusby MJ, Parker CM (1999) Mucosal T lymphocyte numbers are selectively reduced in integrin alpha E (CD103)-deficient mice. J Immunol 162(11):6641–6649

14. Le Floc’h A, Jalil A, Vergnon I, Le Maux Chansac B, Lazar V, Bismuth G, Chouaib S, Mami-Chouaib F (2007) Alpha E beta 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis. J Exp Med 204(3):559–570. https://doi.org/10.1084/jem.20061524

15. Franciszekiewicz K, Le Floc’h A, Boutet M, Vergnon I, Schmitt A, Mami-Chouaib F (2013) CD103 or LFA-1 engagement at the immune synapse between cytotoxic T cells and tumor cells promotes maturation and regulates T-cell effector functions. Cancer Res 73(2):617–628. https://doi.org/10.1158/0008-5472.CAN-12-2569

16. Chua HL, Bhat-Nakshatri P, Clare SE, Morimiy A, Badve S, Nakshatri H (2007) NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 26(5):711–724. https://doi.org/10.1038/sj.onc.1209808

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Affiliations

Sabina Adhikary1,2 · Tanya L. Hoskin3 · Melody L. Stallings-Mann4 · Muhammad Arshad5 · Marlene H. Frost6 · Stacey J. Winham3 · Alvaro Peña5 · Delphine J. Lee7 · Linda M. Murphy6 · Michele Rakoff8 · Lori A. Denison9 · Keith L. Knutson10 · Derek C. Radisky4 · Daniel W. Visscher11 · Amy C. Degnim3

Daniel W. Visscher
dvisscher.daniel@mayo.edu

1 Dirks/Dougherty Laboratory for Cancer Research, John Wayne Cancer Institute, Santa Monica, CA, USA
2 Present Address: Kite Pharma Inc., Santa Monica, CA, USA
3 Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
4 Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA
5 Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
6 Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA
7 Department of Medicine, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, USA
8 Breast Cancer Care and Research Fund, Los Angeles, CA, USA
9 Department of Information Technology, Mayo Clinic, Rochester, MN, USA
10 Department of Immunology, Mayo Clinic, Jacksonville, FL, USA
11 Department of Anatomic Pathology, Mayo Clinic, Rochester, MN, USA